(1S,2R)-1-(2-NAPHTHYL)-2-[(S)-1-AMINOPROPYL]-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE-HYDROCHLORIDE
Compound with spectra: 1 NMR
![(1S,2R)-1-(2-NAPHTHYL)-2-[(S)-1-AMINOPROPYL]-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE-HYDROCHLORIDE](/api/compound/ESGUKHybmP.png?ph=true&h=300&w=458 "(1S,2R)-1-(2-NAPHTHYL)-2-[(S)-1-AMINOPROPYL]-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE-HYDROCHLORIDE")
| SpectraBase Compound ID | ESGUKHybmP |
|---|---|
| InChI | InChI=1S/C21H28N2O.ClH/c1-4-19(22)18-14-21(18,20(24)23(5-2)6-3)17-12-11-15-9-7-8-10-16(15)13-17;/h7-13,18-19H,4-6,14,22H2,1-3H3;1H/t18-,19+,21+;/m0./s1 |
| InChIKey | VJLCLSBGXUVIRT-TVCMNIOLSA-N |
| Mol Weight | 360.93 g/mol |
| Molecular Formula | C21H29ClN2O |
| Exact Mass | 360.196841 g/mol |
| Parent InChIKey | KRCIGINGTCRRTE-QKNQBKEWSA-N |
| Enantiomer InChIKey | VJLCLSBGXUVIRT-LINKRLRISA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CD3OD |
(1S,2R)-1-(2-NAPHTHYL)-2-[(S)-1-HYDROXYPROPYL]-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE
(1S,4S,5R)-2-OXO-4-ETHYL-1-(2-NAPHTHYL)-3-OXABICYCLO-[3.1.0]-HEXANE
(1S,2R)-1-(2-METHYLPHENYL)-2-[(S)-1-AMINOPROPYL]-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE-HYDROCHLORIDE
(1S,2R)-1-(3-METHYLPHENYL)-2-[(S)-1-AZIDOPROPYL]-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE
(1S,2R)-1-(2-FLUOROPHENYL)-2-[(S)-1-HYDROXYPROPYL]-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE
(1S,2R)-1-(2-METHYLPHENYL)-2-[(S)-1-HYDROXYPROPYL]-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE
1-[2-ISOPROPYL-4-MORPHOLINO-2-(1-NAPHTHYL)BUTYRYL]PYRROLIDINE
1-[2-ISOPROPYL-2-(1-NAPHTHYL)-4-PIPERIDINOBUTYRYL]PYRROLIDINE
(1S,2R)-1-(1-NAPHTHYL)-2-FORMYL-N,N-DIETHYLCYCLOPROPANECARBOXAMIDE
Tri(2-azulenyl)-1-methylazetidin-2-one
| Title | Journal or Book | Year |
|---|---|---|
| Synthesis of derivatives of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) modified at the 1-aromatic moiety as novel NMDA receptor antagonists: the aromatic group is essential for the activity | Bioorganic & Medicinal Chemistry | 2002 |